Junshi Biosciences Announces 2023 Full Year Financial
SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading...
Source: globenewswire.com
📰 Junshi Bioscience News
Junshi Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Junshi Bioscience. Real-time updates on events, politics, business and more.
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading…
Source: financialpost.com
Coherus and Junshi Biosciences Announce FDA Approval of
– LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy...
Source: globenewswire.com
Junshi Biosciences Announces Acceptance of the Supplemental
SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading...
Source: globenewswire.com
Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer
SHANGHAI, China, June 29, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and comme...
Source: marketscreener.com
Toripalimab Plus Chemo Elicits Significant OS Improvement in Recurrent or Metastatic Nasopharyngeal Carcinoma
First-line treatment with toripalimab in combination with gemcitabine and cisplatin resulted in a statistically significant and clinically meaningful improvement in overall survival and progression-free survival vs placebo plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma.
Junshi Bioscience Coherus Biosciences Junshi Biosciences Coherus Biosciences Inc Shanghai Junshi Biosciences Co Ltd Maih Q
Source: onclive.com
Sub: Transcript of the Earnings call conducted on May 10, 2023 - Form 6-K
Sub: Transcript of the Earnings call conducted on May 10, 2023 Pursuant to Regulation 30 of Securities and Exchange Board of India Regulations, 2015, please find enclosed the... | May 16, 2023
Source: marketscreener.com
Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries
SHANGHAI, China, May 07, 2023 -- Shanghai Junshi Biosciences Co., Ltd announced a collaboration with Dr. Reddy’s Laboratories Limited to develop and commercialize toripalimab, the anti-PD-1... | May 7, 2023
Source: marketscreener.com
Junshi Biosciences Announces Collaboration with Dr. Reddy's
SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced a...
Source: globenewswire.com
Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddys Laboratories Limited ("Dr.
Source: einnews.com